Detailed information for compound 1764372

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 308.358 | Formula: C16H12N4OS
  • H donors: 1 H acceptors: 3 LogP: 3.28 Rotable bonds: 3
    Rule of 5 violations (Lipinski): 1
  • SMILES: Nc1nc(nc2c1cc(s2)Cc1ccccc1)c1ncco1
  • InChi: 1S/C16H12N4OS/c17-13-12-9-11(8-10-4-2-1-3-5-10)22-16(12)20-14(19-13)15-18-6-7-21-15/h1-7,9H,8H2,(H2,17,19,20)
  • InChiKey: WBPDJKYORJQJOS-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens adenosine A2a receptor Starlite/ChEMBL References
Homo sapiens adenosine A1 receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi follicle stimulating hormone receptor adenosine A2a receptor 412 aa 336 aa 22.3 %
Brugia malayi hypothetical protein adenosine A1 receptor 326 aa 305 aa 21.0 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni 6-phosphofructokinase 0.0429 1 0.5
Giardia lamblia Hypothetical protein 0.0253 0.2852 0.5
Mycobacterium ulcerans fructose-2,6-bisphosphatase GpmB 0.0253 0.2852 0.5
Trypanosoma cruzi 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative 0.0429 1 1
Trypanosoma cruzi 6-phosphofructo-2-kinase 1 0.0421 0.9706 0.9706
Giardia lamblia Hypothetical protein 0.0253 0.2852 0.5
Loa Loa (eye worm) hypothetical protein 0.0429 1 1
Trypanosoma cruzi 6-phosphofructo-2-kinase 1 0.0421 0.9706 0.9706
Leishmania major 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative 0.0429 1 1
Trypanosoma brucei 6-phosphofructo-2-kinase 2 0.0421 0.9706 0.9706
Onchocerca volvulus 0.0429 1 0.5
Leishmania major 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative 0.0421 0.9706 0.9706
Echinococcus multilocularis 6 phosphofructo 2 kinase:fructose 2 0.0429 1 0.5
Trypanosoma brucei 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative 0.0429 1 1
Loa Loa (eye worm) hypothetical protein 0.0421 0.9706 0.9604
Mycobacterium ulcerans hypothetical protein 0.0253 0.2852 0.5
Entamoeba histolytica phosphoglycerate mutase family protein, putative 0.0253 0.2852 0.5
Trypanosoma cruzi 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative 0.0429 1 1

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) Antiparkinsonian activity in mouse assessed as reversal of haloperidol-induced catalepsy at 3 mg/kg, po after 1 hr ChEMBL. 23522563
Ki (functional) = 4.7 nM Antagonist activity at human adenosine A2a receptor expressed in CHOK1 cells assessed as inhibition of NECA/forskolin-induced cAMP accumulation incubated for 15 mins prior to NECA/forskolin challenge measured after 5.5 to 6 hrs by beta-galactosidase reporter gene assay ChEMBL. 23522563
Ki (functional) = 310 nM Antagonist activity at human adenosine A1 receptor expressed in CHOK1 cells assessed as inhibition of R-PIA/forskolin-induced cAMP accumulation incubated for 15 mins prior to R-PIA/forskolin challenge measured after 5.5 to 6 hrs by beta-galactosidase reporter gene assay ChEMBL. 23522563

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.